Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So Shingrix was 4%, 11% in the first two years, so this -- it did better than we're expecting |
| We’ve also got experiments and we've had excellent study result, exploratory study that was best of ASCO last year or one of the two best of ASCO and locally advanced rectal cancer |
| We've published this, we've got really good data on Serotype 3 and it's five and 19 from memory is what we're doing |
| And then you've got Europe, which with each year of incremental efficacy, we get a stronger position |
| And if remission becomes more and more in the minds of physicians that's going to remain earlier initiation, then long acting antibodies are really going to become very, very compelling |
| Better outcomes, better adherence in the physician treatment fine [ph] bill et cetera |
| Lupus nephritis is going very well, so it's a very durable product |
| I think if we can get to functional cure rates in the 20s or 30s, then we have a very exciting product |
| Its 12 months flu like symptoms and you have life-long treatment to maintain that, so, yes, we've seen good efficacy |
| But again, we've got really good traction in that first line setting |
| It is quite impressive how you’ve done so well in this market |
| And, yes, we're seeing really good penetration |
| And it's upside for us |
| I'm sure they've gone and had a very good think and they’re going to come out very strong in the next round |
| If we can keep doing intelligent business development as well, yes, I think we've got momentum and we've shown that if we do have an asset, we can compete against the best in the business and hold our own, or more than hold our own commercially |
| Is that a new run rate, or was there something unusual about Q4? How should we think about that? Luke Miels I mean, I think it's us getting traction and the market research we've got is very encouraging for this product |
| So yes, it's really exciting |
| We feel very confident about that based on the effort we've seen and the efficacy we expect |
| I think you've beaten consensus in the last 10 quarters, so I think you do have momentum for sure |
| I think that's quite exciting |
| You've done really well competitively |
| Not everything's going to work, but we're in a much better place than we were a few years ago |
| And yes, we've shown good activity in the low S-antigen population and efficacy here is very marginal, it's 2% to 8% depending on the regimen that you use and the regimens are pretty tough on patients |
| And then there's nasal polyps, which we've been very encouraged by the speed of adoption by ENT surgeons |
| I mean, if you look at the trajectory at launch, it's several orders of magnitude better than pegaptanib and [indiscernible] |
| We've been very disciplined on pricing, but we've had a lot of success in Germany, where we moved early and starting to now get contracts and government reimbursement in markets across Europe |
| And there's actually a larger population, I think it's about 5 million in Europe that have hep B as well, so it's a really attractive product and oligonucleotide it's hard to make, but we have -- we've got a pathway to build that |
| So, yes, exciting, high awareness, high intention to prescribe and, yes, we'll see where we go over the next few months, but our intent is to take insight on head on and really challenge them for the anemic population |
| And we were really excited with the concept of the off-target effect of momelotinib and ACVR1, and just the elegance of positioning it solely for patients with anemia |
| The other upside is if we can get broader approval in the MRP, so shorter duration, but obviously a bigger number of patients, but that's the primary driver |
| Statement |
|---|
| And then you've got obviously competitive pressure on the circulating serotype that evolves over time |
| And in some clinics, we are really challenging ruxolitinib |
| Even if they did make it to market, I think there's going to be a reluctance to employ them |
| And then if you look at Gefapixant, they're losing big numbers of patients quite quickly within a couple of weeks |
| The challenge is establishing efficacy in SLE is very difficult and you've got active drugs that have failed Phase 3 programs, and so it's not a risk free proposition for a biosimilar to develop |
| I mean, there is a scenario where you never need it, but I think that's unlikely because these are older individuals at high risk of getting shingles with declining immune system |
| We've got a new formulation which lowers the cost of goods outside the U.S., which has been an impediment for us ex-U.S., so we're starting to see some traction there |
| We ourselves were disrupted many years ago by Pfizer |
| I think there's very little |
| So that's we knew all of that |
| There's also the challenge of having to use EPO, having to do transfusions |
| I thought it'd be a bit more of a cautious uptake |
| If they do get traction there, and look, there's been a high failure rate and bet most recently as well, arguably, at least based on historical FDA decision making |
| That's a pathfinder way of entering the market and then ultimately our aim is to really disrupt this market with the 30 plus technology a couple of years later |
| Pfizer is not a weak company yet |
| What is the one thing that we are missing that we will all see in five or 10 years? Luke Miels I mean, the problem is if you're sitting inside, okay, now you're probably heavily biased too, but I've seen this movie before |
| CAR Ts looked interesting, but are probably unlikely to be |
| Now, the rheumatologists coming through, graduating now they can use the antibodies from day one, so I think that's only going to increase |
| Yet, the burden is there |
| We didn't see breakthrough events yet |
Please consider a small donation if you think this website provides you with relevant information